Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Manny Gugliuzza who wrote (288)	3/18/1998 1:34:00 PM
From: Easy Mark	Read Replies (1) \| Respond to of 1510

The important issue is not efficiency or cost of goods sold. The issue is providing rock solid evidence that their production process is safe, reliable, and has quality control. Without that evidence, FDA could approve Remune but hold up distribution. IRC's existing production capability (even with 50% efficiency) is sufficient to supply a large fraction of the US AIDS population. The steps taken now to provide quality assurance are vital to ensuring that production capability produces revenue in 1999. It is comforting to see work proceeding on schedule to demonstrate quality control. It is also comforting that IRC has not taken the premature step of issuing a press release regarding their quality control procedures.